Viveve Medical Inc (NASDAQ:VIVE) Short Interest Update

Viveve Medical Inc (NASDAQ:VIVE) was the target of a large drop in short interest in the month of March. As of March 13th, there was short interest totalling 149,500 shares, a drop of 48.6% from the February 27th total of 291,000 shares. Approximately 3.8% of the shares of the company are sold short. Based on an average daily volume of 734,900 shares, the days-to-cover ratio is currently 0.2 days.

A number of equities research analysts have recently commented on VIVE shares. ValuEngine cut shares of Viveve Medical from a “buy” rating to a “hold” rating in a research note on Friday, February 7th. LADENBURG THALM/SH SH raised shares of Viveve Medical from a “neutral” rating to a “buy” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. Viveve Medical has an average rating of “Hold” and an average price target of $0.60.

Viveve Medical stock opened at $0.76 on Friday. The company’s fifty day moving average price is $1.01 and its 200 day moving average price is $2.04. Viveve Medical has a 1 year low of $0.54 and a 1 year high of $104.00. The stock has a market capitalization of $910,000.00, a P/E ratio of -0.01 and a beta of 0.24. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.75 and a current ratio of 3.52.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Read More: How to Invest in Growth Stocks

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.